Generics may be allowed to change drug labelling

Home/Policies & Legislation | Posted 02/08/2013 post-comment0 Post your comment

FDA has proposed a new rule which would allow generics makers to change their labelling in the same way as brand-name manufacturers.

Law V13C29

Under current regulations generics manufacturers cannot update the labelling of their products until the brand-name manufacturer does so. Many potential hazards, however, are not discovered until years after drugs have been on the market, yet, these regulations mean that generics manufacturers can do little to warn doctors and patients about newly discovered information, potentially putting patients at risk.

A new rule being proposed by FDA could change this, enabling ‘the labelling of an approved drug to reflect certain types of newly acquired information in advance of FDA’s review of such change’ and creating parity between generics and brand-name drugmakers with respect to supplemental labelling requirements.

The decision by FDA comes two years after the US Supreme Court ruled in June 2011 that generics makers were pre-empted by federal law from being sued for failing to provide adequate label warnings about potential side effects [1]. Then in June 2013 the same court ruled that generics makers could not be sued by patients for any injuries. This is due to the fact that generics manufacturers either need FDA to order a label change or the brand-name manufacturer to do it first.

The new rule could potentially open up generics makers to law suits, such as that of Mutual Pharmaceutical versus Bartlett, with lawyers for injured patients arguing that generic drugs were unreasonably dangerous if they could have changed their labelling to give extra warnings but didn’t.

Related articles

Generics drugmakers should be held responsible for injuries

Brand-name and generics labels don’t match

Generic pre-emption raises its ugly head again


1.  GaBI Online - Generics and Biosimilars Initiative. Generics manufacturers do not have to change drug safety labels in the US []. Mol, Belgium: Pro Pharma Communications International; [cited 2013 Aug 2]. Available from:

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2013 Pro Pharma Communications International. All Rights Reserved.

Source: LA Times, OIRA, Public Citizen, The Hill

comment icon Comments (0)
Post your comment
Related content
FDA publishes final Q&A on biosimilar development and the BPCI Act
Home/Policies & Legislation Posted 15/10/2021
FDA voices concerns around drug patents and competition
Patent 1 V13E17
Home/Policies & Legislation Posted 08/10/2021
USA BIOSIM Act introduction
02 AA010638
Home/Policies & Legislation Posted 17/09/2021
Most viewed articles
About GaBI
Home/About GaBI Posted 05/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010